Loading...
•
Sep 30, 2023
Theravance Q3 2023 Earnings Report
Theravance Biopharma reported bottom line performance driven by YUPELRI growth and expense management.
Key Takeaways
Theravance Biopharma announced its Q3 2023 financial results, highlighting YUPELRI growth and expense management leading to a non-GAAP loss of less than $1 million. The company is progressing with the Phase 3 CYPRESS study for ampreloxetine.
Bottom line performance in Q3 was driven by YUPELRI growth and expense management.
Non-GAAP loss of less than $1 million was reported.
Phase 3 CYPRESS study for ampreloxetine is ongoing.
Áine Miller, Ph.D., will assume the role of SVP, Development at Theravance Biopharma.
Theravance
Theravance
Forward Guidance
No specific financial guidance was provided in the current earnings report.